- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01274897
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of
- Department of Pediatrics, Kosin University Gospel Hospital
-
Gyeonggi-do, Korea, Republic of
- Department of Pediatrics, Seoul National University Bundang Hospital
-
Incheon, Korea, Republic of
- Deaprtment of Pediatrics, Inha University Hospital
-
Incheon, Korea, Republic of
- Division of Infectious Diseases, Inha University Hospital
-
Kyunggi, Korea, Republic of
- Pediatrics and Adolescent medicine, Myongji Hospital Kwandong University
-
Seoul, Korea, Republic of
- Department of Pediatrics, Ewha Womans University Mokdong Hospital
-
Seoul, Korea, Republic of
- Division of Infection Diseases, Seoul National University Hospital
-
Seoul, Korea, Republic of
- Division of Infectious Diseases, Korea University Guro Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals eligible for enrollment in this study were those:
who were 11-55 years of age inclusive and who, after the nature of the study had been explained:
- had given written assent and/or for whom the parent/legal representative had provided written informed consent (11-19 years of age).
- had provided written informed consent (20-55 years of age).
- who the investigator believed that they or their parents/legal representatives would comply with the requirements of the protocol (e.g., completion of the Diary Card, return for follow-up visit).
who were in good health as determined by
- medical history
- physical assessment
- clinical judgment of the investigator
- who had negative urine pregnancy test for women of childbearing age.
Exclusion Criteria:
Individuals not eligible to be enrolled in the study were those:
- who were unwilling or unable to give written informed assent or consent to participate in the study.
- who were perceived to be unreliable or unavailable for the duration of the study period.
- who were planning to leave the area of the study site before the end of the study period.
- who had a previous or suspected disease caused by N. meningitidis.
- who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrollment.
- who had previously been immunized with a meningococcal vaccine.
- who had received any investigational or non-registered product (drug or vaccine)within 28 days prior to enrollment or who expected to receive an investigational drug or vaccine prior to the completion of the study.
- who had received any licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this study or who were planning to receive any vaccine within 30 days from the study vaccines. (Exception: Influenza vaccine was administered up to 15 days prior to study vaccination and at least 15 days after study vaccination)
- who had experienced within the 7 days prior to enrollment significant acute or chronic infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥38°C) within 3 days prior to enrollment.
- who had any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition).
- who had epilepsy or any progressive neurological disease.
- who had a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components, including latex allergies.
who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):
- received immunosuppressive therapy within 28 days prior to enrollment(any systemic corticosteroid administered for more than 5 days, or in a daily dose > 1 mg/kg/day prednisone or equivalent during any of 28 days prior to enrollment, or cancer chemotherapy)
- received immunostimulants
- received parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study
- who were known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- who had any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MenACWY-CRM
Subjects received one dose of MenACWY-CRM conjugate vaccine.
|
All subjects had blood drawn at Day 1 and Day 29.
|
Placebo Comparator: Placebo
Subjects received the saline placebo.
|
All subjects had blood drawn at Day 1 and Day 29.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentages of Subjects With Seroresponse, Directed Against Neisseria Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.
Time Frame: day 29
|
Immunogenicity was measured as the percentage of subjects with hSBA response and associated 95% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y by serum bactericidal assay using human complement, human serum bactericidal assay (hSBA), at day 29 (28 days after MenACWY-CRM vaccination). Seroresponse is defined as:
|
day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Titers (GMTs) of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.
Time Frame: day 1 and day 29
|
Immunogenicity was assessed as hSBA GMTs and associated 95% CI, measured against N. meningitidis serogroups A, C, W and Y, before the vaccination (baseline, day 1) and at day 29 (28 days after MenACWY-CRM vaccination).
|
day 1 and day 29
|
Percentages of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y After MenACWY-CRM Vaccination.
Time Frame: day 1 and day 29
|
Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI, at baseline before vaccination (day 1) and at day 29 (28 days after MenACWY-CRM vaccination).
|
day 1 and day 29
|
Number of Subjects Who Reported Local and Systemic Reactogenicity During 7 Days After MenACWY-CRM Vaccination
Time Frame: during 7 days of vaccination
|
during 7 days of vaccination
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Meningitis, Bacterial
- Central Nervous System Bacterial Infections
- Neisseriaceae Infections
- Meningitis, Meningococcal
- Meningitis
- Meningococcal Infections
- Gastrointestinal Agents
- Cathartics
- Lactitol
Other Study ID Numbers
- V59_39
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningococcal Disease
-
PfizerCompletedMeningococcal B DiseaseAustralia, Poland, Finland, Czechia
-
PfizerCompleted
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
University of OxfordGlaxoSmithKline; Oxford University Hospitals NHS TrustCompletedInvasive Meningococcal DiseaseUnited Kingdom
-
University of OxfordNorwegian Institute of Public Health; Wellcome TrustCompletedSerogroup B Meningococcal DiseaseUnited Kingdom
-
Serum Institute of India Pvt. Ltd.Completed
-
Novartis VaccinesNovartisCompletedPrevention of Meningococcal DiseaseUnited States
-
Novartis VaccinesCompletedPrevention of Meningococcal DiseaseUnited States
-
Canadian Paediatric SocietyGlaxoSmithKline; PfizerRecruitingInvasive Meningococcal DiseaseCanada
-
Canadian Immunization Research NetworkUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaboratorsCompleted
Clinical Trials on Novartis MenACWY-CRM
-
University of OxfordCompletedMeningitis | Meningococcal Disease | SepticaemiaUnited Kingdom
-
Novartis VaccinesNovartisCompletedMeningococcal Disease | Meningococcal MeningitisUnited States
-
Novartis VaccinesCompletedMeningococcal InfectionsUnited States
-
Canadian Immunization Research NetworkUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaboratorsCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesNovartisCompleted
-
GlaxoSmithKlineCompletedMeningococcal DiseaseKorea, Republic of
-
Novartis VaccinesNovartisCompletedPrevention of Meningococcal DiseaseUnited States
-
Novartis VaccinesCompleted